[PDF] Pharmaceutical pricing : early access, the Cancer Drugs Fund and the role of NICE. Policy and research briefing

Source:
Centre for Health Economics - CHE
Publisher:
Centre for Health Economics (CHE)
Publication date:
24 March 2016

Abstract

The real problem that NHS patients face in accessing new medicines and that manufacturers face in getting market access and an early return on their investments has been, and remains, the discrepancy between the prices charged and how much the NHS can afford to pay for the benefits that new medicines offer.